Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 23;6(2):73–76. doi: 10.1080/21655979.2015.1011039

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 3. — Tissue-engineered bone models express osteomimicry. (a) Tissue-engineered (TE) model of Ewing's sarcoma. Bone markers BSP, OPN and OCN are re-expressed in the TE-Ewing's sarcoma 3D model, as shown histologically (hematoxylin and eosin) and by immunostains (Ewing's sarcoma marker CD99; bone markers BSP, OPN and OCN) after 6 weeks of culture. Negative control without primary antibody is shown for comparison. Counterstaining was performed with hematoxylin QS (blue). (b) Marker expression after 4 weeks in co-culture. Data are shown for bone pellets in co-culture with Ewing's sarcoma aggregates. Immunohistochemical stainings of the aggregates model for Ewing's sarcoma marker CD99 and bone marker OCN at week 4 in co-culture with osteoblasts-derived from hMSC. Negative control without primary antibody is shown for comparison. OB = Osteoblasts; ES = Ewing's sarcoma cells. (Reproduced with permission from Villasante et al. Biomaterials 2014; 35: 5785-94).